Abstract:Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. Herein, we report our effort on the discovery, optimization, and evaluation of benzothiazole and benzimidazole derivatives as novel inverse agonists of RORγ. The representative compound 27h (designated as XY123) potently inhibited the RORγ transcription activity with a half-maximal inhibitory concentration (IC50) value of 64 nM and showed excellent selectivity against other nuclear receptors. 27h also potently suppressed cell proliferation, colony formation, and the expression of androgen receptor (AR)-regulated genes in AR-positive prostate cancer cell lines. In addition, 27h demonstrated good metabolic stability and a pharmacokinetic property with reasonable oral bioavailability (32.41%) and moderate half-life (t1/2 = 4.98 h). Significantly, oral administration of compound 27h achieved complete and long-lasting tumor regression in the 22Rv1 xenograft tumor model in mice. Compound 27h may serve as a new valuable lead compound for further development of drugs for the treatment of prostate cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00763?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00763</a>.Virtual screening results from the molecular docking; compounds identified as hits against RORγ from virtual screening; overlaid complex structures of compound XY101 and compound 27h; overlaid structures of compounds 27g and 27h; western blot analysis of the AR and AR variants levels in 22Rv1 cells treated with compound 27h; metabolic stability of 25c, 25p, 27g, and 27h in human and rat liver microsomes; 1H and 13C NMR spectra of the synthesized compounds; and HPLC traces of representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_001.pdf">PDF</a>)Molecular formula strings for compounds with associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_002.csv">CSV</a>)Database files (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[ d ]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD)

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Discovery of a novel GPR35 agonist with high and equipotent species potency for oral treatment of IBD

Discovery of Orally Available Retinoic Acid Receptor-Related Orphan Receptor -t/Dihydroorotate Dehydrogenase Dual Inhibitors for the Treatment of Refractory Inflammatory Bowel Disease

Discovery of Orally Available Retinoic Acid Receptor-Related Orphan Receptor γ-t/Dihydroorotate Dehydrogenase Dual Inhibitors for the Treatment of Refractory Inflammatory Bowel Disease

Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84

Discovery of a First-in-Class GPR183 Antagonist for the Potential Treatment of Rheumatoid Arthritis

Discovery of Novel Imidazo[4,5- c ]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis

Discovery of novel N2-indazole derivatives as phosphodiesterase 4 inhibitors for the treatment of inflammatory bowel disease

Phosphodiesters as GPR84 Antagonists for the Treatment of Ulcerative Colitis

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

SPH7854, a gut-limited RORγt antagonist, ameliorates TNBS-induced experimental colitis in rat

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist

Aminosalicylates target GPR35, partly contributing to the prevention of DSS-induced colitis

Discovery of chiral N-2′-aryletheryl-1′-alkoxy-ethyl substituted arylisoquinolones with anti-inflammatory activity from the nucleophilic addition reactions of the thiophenols and oxazolinium

Discovery of 6‐Acylamino/Sulfonamido Benzoxazolone with IL‐6 Inhibitory Activity as Promising Therapeutic Agents for Ulcerative Colitis

Synthesis and Anti-Inflammatory Bowel Disease Activity of Pterostilbene Derivatives

Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis

Identification of novel indolinone derivatives as CTSC inhibitors to treat inflammatory bowel disease by modulating inflammatory factors